Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Anika Therapeutics (ANIK) Debt to Equity (2020 - 2022)

Anika Therapeutics has reported Debt to Equity over the past 7 years, most recently at $0.02 for Q2 2022.

  • Quarterly Debt to Equity fell 74.36% to $0.02 in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $0.02 through Jun 2022, down 74.36% year-over-year, with the annual reading at $0.02 for FY2021, 68.72% down from the prior year.
  • Debt to Equity was $0.02 for Q2 2022 at Anika Therapeutics, roughly flat from $0.02 in the prior quarter.
  • Over five years, Debt to Equity peaked at $0.17 in Q2 2020 and troughed at $0.01 in Q3 2021.
  • The 3-year median for Debt to Equity is $0.05 (2020), against an average of $0.06.
  • Year-over-year, Debt to Equity tumbled 66.07% in 2021 and then plummeted 83.24% in 2022.
  • A 3-year view of Debt to Equity shows it stood at $0.05 in 2020, then tumbled by 68.72% to $0.02 in 2021, then grew by 0.33% to $0.02 in 2022.
  • Per Business Quant, the three most recent readings for ANIK's Debt to Equity are $0.02 (Q2 2022), $0.02 (Q1 2022), and $0.02 (Q4 2021).